ZA94186B - Agents for vascular diseases - Google Patents

Agents for vascular diseases

Info

Publication number
ZA94186B
ZA94186B ZA94186A ZA94186A ZA94186B ZA 94186 B ZA94186 B ZA 94186B ZA 94186 A ZA94186 A ZA 94186A ZA 94186 A ZA94186 A ZA 94186A ZA 94186 B ZA94186 B ZA 94186B
Authority
ZA
South Africa
Prior art keywords
endothelin
endothelins
analogues
derivatives
partial sequences
Prior art date
Application number
ZA94186A
Inventor
Ludger Dr Dinkelborg
Sebastian Dr Erber
Christoph Stephan Dr Hilger
Wolfgang Dr Kramp
Hans-Martin Dr Schier
Ulrich Prof Dr Speck
Heinz Dr Gries
Johannes Dr Patzek
H Joseph Reiser
Original Assignee
Diagnostikforschung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostikforschung Inst filed Critical Diagnostikforschung Inst
Publication of ZA94186B publication Critical patent/ZA94186B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Abstract

The present invention relates to metal complexes and metal complex conjugates of endothelins, endothelin derivatives, partial sequences of endothelins, endothelin analogues or endothelin antagonists, iodinated endothelin derivatives, partial sequences of endothelins, endothelin analogues or endothelin antagonists, and to compositions containing these compounds, to their preparation as diagnostic agents, and to processes for the preparation of these compounds and compositions. Used for this purpose are metal complexes and metal complex conjugates of endothelins, endothelin derivatives, partial sequences of endothelins, endothelin analogues or endothelin antagonists, as well as iodinated endothelin derivatives, partial sequences of endothelins, endothelin analogues or endothelin antagonists, which can be administered in vivo, preferably for the non-invasive imaging of vascular disorders.
ZA94186A 1993-01-13 1994-01-12 Agents for vascular diseases ZA94186B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301871A DE4301871A1 (en) 1993-01-13 1993-01-13 New means of diagnosing vascular diseases

Publications (1)

Publication Number Publication Date
ZA94186B true ZA94186B (en) 1994-08-18

Family

ID=6478840

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94186A ZA94186B (en) 1993-01-13 1994-01-12 Agents for vascular diseases

Country Status (9)

Country Link
EP (1) EP0606683B1 (en)
JP (1) JP3558169B2 (en)
KR (1) KR100330794B1 (en)
AT (1) ATE230416T1 (en)
AU (1) AU666059B2 (en)
CA (1) CA2113245A1 (en)
DE (2) DE4301871A1 (en)
IL (1) IL108322A (en)
ZA (1) ZA94186B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425778A1 (en) * 1994-07-13 1996-01-18 Diagnostikforschung Inst Complex compounds for the diagnosis of vascular diseases
DE4428851C2 (en) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Nanoparticles containing iron, their production and application in diagnostics and therapy
DE19536783A1 (en) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunctional nicotinamide chelating agents of the type N¶2¶S¶2¶ for radioactive isotopes
DE19652374A1 (en) * 1996-12-04 1998-06-10 Schering Ag Use of endothelin conjugates in therapy, new endothelin conjugates, agents containing them, and processes for their preparation
ES2206689T3 (en) * 1996-10-28 2004-05-16 Amersham Health As CONTRAST AGENTS.
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CA2324555A1 (en) 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
JP2002532440A (en) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー Vitronectin receptor antagonist drug
US6558649B1 (en) 1998-12-18 2003-05-06 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
KR100675356B1 (en) * 2005-04-29 2007-02-01 경희대학교 산학협력단 Chelating agent comprising novel amide compound used in metal-extracting using supercritical or liquid state fluid, metal-extracting method and metal-extracting system using said chelating agent
GB0513812D0 (en) * 2005-07-05 2005-08-10 Isis Innovation Compounds for imaging and therapy
CN103705947A (en) 2006-06-28 2014-04-09 株式会社Ihi Drug, drug induction device, magnetic detector and method of designing drug
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (en) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa Iron salen complex, medicine having magnetism, guiding system of medicine and device for detecting magnetism
WO2010058280A1 (en) 2008-11-20 2010-05-27 株式会社Ihi Auto magnetic metal salen complex compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188256B1 (en) * 1985-01-14 1991-08-21 NeoRx Metal radionuclide labeled proteins for diagnosis and therapy
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
GB8913089D0 (en) * 1989-06-07 1989-07-26 Ciba Geigy Japan Ltd Novel endothelin derivative
US5306808A (en) * 1990-02-26 1994-04-26 Takeda Chemical Industries, Ltd. Peptide derivatives having vasodilating activity
CA2080493A1 (en) * 1990-05-03 1991-11-04 Robert S. Lees Synthetic peptides for arterial imaging
DK0629133T3 (en) * 1992-01-03 2001-04-02 Rhomed Inc Pharmaceutical use of peptide metal ions

Also Published As

Publication number Publication date
ATE230416T1 (en) 2003-01-15
DE4301871A1 (en) 1994-07-14
JP3558169B2 (en) 2004-08-25
EP0606683A2 (en) 1994-07-20
JPH07149799A (en) 1995-06-13
KR100330794B1 (en) 2002-07-27
AU5314694A (en) 1994-07-21
DE59310320D1 (en) 2003-02-06
EP0606683A3 (en) 1995-12-27
KR940018398A (en) 1994-08-16
EP0606683B1 (en) 2003-01-02
IL108322A (en) 2001-05-20
IL108322A0 (en) 1994-04-12
AU666059B2 (en) 1996-01-25
CA2113245A1 (en) 1994-07-14

Similar Documents

Publication Publication Date Title
ZA94186B (en) Agents for vascular diseases
DE60043197D1 (en)
IL145830A (en) Glucagon-like peptide-1 compositions for use in treating myocardial tissue injury
GB9006977D0 (en) Compositions
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
HK1016877A1 (en) Bioactivated diagnostic imaging contrast agents.
IL133585A0 (en) Soluble prodrugs of paclitaxel
GB2128088B (en) Oral mopidamol preparations
UA32577C2 (en) Radiolabeled compound as imaging agents for the diagnosis of arterial and venous thrombi, radiopharmaceuticals and radiopharmaceutical composition and kits for its preparation
EP0458079A3 (en) Ultrasonic contrast agent, its preparation and application as diagnostic or therapeutic
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
MY104535A (en) Oral composition for the treatment of inflammatory bowel diseases.
RU92004368A (en) SUBSTITUTED PYRIMIDINES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION
AU9245601A (en) Peptide-based compounds
NZ235499A (en) Radiolabelled hirudin analogues, pharmaceutical compositions and in vitro and in vivo detection of thrombin
YU33203A (en) Radiopharmaceuticals for diagnosing alzheimer's disease
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
MXPA03009553A (en) Use of bile acid or bile salt fatty acid conjugates.
DE60334711D1 (en) EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS
HU902004D0 (en) New trombolitic preparations
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
HUP9901247A3 (en) Use of naphthimidazole-, naphthoxazole- and naphthothiazole-diones for the preparation of pharmaceutical compositions treating diseases caused by vascular function deficiency
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001080906A3 (en) Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
AU1200488A (en) Protein c inhibitor (pci) as pharmaceutical and in vitro diagnostic aid, a process for the preparation of a pharmaceutical or diagnostic aid of this type, and an agent containing pci